Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
| ▸ | GRM5 | P41594 | 7/20 | 0.40 |
| ▸ | GRAMD1A | Q96CP6 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 7/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL978100 | 0.76 | F10 (0.52) | HDAC3HDAC1HDAC6F10ALOX15 | |
| SCHEMBL26420713 | 0.76 | DPP4 (0.48) | GRM5NPC1RAB9A | |
| SCHEMBL976678 | 0.75 | NPC1 (0.42) | GRM5NPC1RAB9AF10 | |
| SCHEMBL10825515 | 0.74 | RAD52 (0.48) | GRM5GRAMD1ANPC1RAB9AALDH1A1 | |
| SCHEMBL975378 | 0.73 | HDAC3 (0.46) | HDAC3HDAC1HDAC6NPC1RAB9A | |
| SCHEMBL29397882 | 0.72 | ADRA2A (0.49) | GRM5GRAMD1ANPC1RAB9A | |
| SCHEMBL10764703 | 0.71 | GRAMD1A (0.43) | GRAMD1ANPC1RAB9AALOX15TSHR | |
| Dimethylamine SCHEMBL10825447 | 0.71 | DPP4 (0.43) | GRM5NPC1RAB9A | |
| SCHEMBL741569 | 0.71 | F10 (0.56) | F10 | |
| SCHEMBL31143542 | 0.70 | ADORA1 (0.51) | GRAMD1AF10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021494-A1 | NOVEL TETRAHYDRO-FUSED PYRIDINES AS HISTONE DEACETYLASE INHIBITORS | 4SC AG (DE) | 2011-01-27 | — | — | US | claimed |
| US-20110021494-A1 | NOVEL TETRAHYDRO-FUSED PYRIDINES AS HISTONE DEACETYLASE INHIBITORS | 4SC AG (DE) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021494-A1 | NOVEL TETRAHYDRO-FUSED PYRIDINES AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC3 | HDAC3 3/4885HDAC1 1/4885HDAC6 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.